Non-cash compensation expense related to equity awards for the three and six months ended June 30, 2026 increased compared to the same periods in 2025 due to a higher stock price on the grant date of annual equity awards in 2026 compared to 2025 and increased headcount.

filing / Jul 29, 2026 / receipt

Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2026.

filing / Jul 29, 2026 / receipt

Similarly, cost control initiatives by governments or third-party payers could decrease the price received for our medicines or increase patient coinsurance to a level that makes our medicines, including our commercial medicines and our medicines in development, economically unviable.

filing / Jul 29, 2026 / receipt

Non-cash compensation expense related to equity awards for the three months ended March 31, 2026 increased compared to the same period in 2025 due to a higher stock price on the grant date of annual equity awards in 2026 compared to 2025 and increased headcount.

filing / Apr 29, 2026 / receipt

Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026.

filing / Apr 29, 2026 / receipt

Similarly, cost control initiatives by governments or third-party payers could decrease the price received for our medicines or increase patient coinsurance to a level that makes our medicines, including our commercial medicines and our medicines in development, economically unviable.

filing / Apr 29, 2026 / receipt